| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
EUDA Health Holdings Limited Ordinary Shares$14.3
+0.02 (+0.14%)
Market Cap
16.90 M
EPS
-
P/E Ratio
-
Value Trade
54.46 K
SEC Financials
Q4 2024Revenue
40.10 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Burn Trend
SEC Filing
Jul 31, 2023
Overview
Volume
4.69 K
52 Week Range
6.42 - 86
% held by Insiders
49.42 %
% held by Institutions
0.04 %
Enterprise Value
-
Total Shares
37.83 M
Short %
0.04 %
Float Shares
18.73 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EUDA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
EUDA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
EUDA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
EUDA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
EUDA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
EUDA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-EUDA
Jun 1, 2026EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market's Continued Listing Requirements After receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency Singapore
EUDA Health Holdings Limited has regained compliance with the Nasdaq Capital Market's continued listing requirements after a prior notification regarding a minimum market value deficiency. The company received a notice on April 23, 2026, for failing to meet the minimum market value of $35 million for over 32 consecutive business days. However, a subsequent notice on May 28 confirmed that the company had maintained the required market value for ten consecutive business days, restoring its compliance status.
Read more →-EUDA
Jun 1, 2026EUDA Health Expands Helix Product Line with Launch of Regenix iPSC-Derived Skin Stem Cell Secretome Mask SINGAPORE
EUDA Health Holdings Limited announced the expansion of its Helix product line with the launch of the Regenix iPSC-derived Skin Stem Cell Secretome Mask. This face mask utilizes advanced secretome technology aimed at enhancing skin hydration and recovery. With the global face mask market projected to grow significantly, EUDA plans to capitalize on its distribution networks and partnerships to drive sales in Asia-Pacific, particularly focusing on market demand in countries like China and Malaysia.
Read more →-EUDA
Apr 28, 2026EUDA Highlights Shenzhen Inno's Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development SINGAPORE
EUDA Health Holdings Limited announced that Shenzhen Inno Immune Co., Ltd. has received approval for its TCR-T cell therapy project under the Shenzhen Key Industry R&D Program. This government initiative aims to support technological innovation and industrial development, with funding of approximately US$434,688 expected for the project. The therapeutic focus is on developing TCR-T therapies targeting solid tumors, utilizing cutting-edge AI-driven screening technologies. This collaboration positions EUDA to expand its distribution of advanced treatments and underscores its commitment to innovative healthcare solutions.
Read more →-EUDA
Apr 27, 2026EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities Singapore.
EUDA Health Holdings Limited has received a notice from Nasdaq indicating its failure to maintain the minimum market value of listed securities at $35 million. The company has a compliance period of 180 days, until October 20, 2026, to meet the required market value for at least ten consecutive business days. Failure to comply could result in delisting, although the company may appeal any delisting determination from Nasdaq. There are no assurances that compliance can be regained during this period.
Read more →-EUDA
Mar 19, 2026EUDA Announces Reverse Stock Split of its Ordinary Shares SINGAPORE
EUDA Health Holdings Limited has announced a reverse stock split of its ordinary shares at a 1-for-20 ratio, effective March 23, 2026. This decision, approved by its Board of Directors, aims to consolidate shares and potentially enhance share price perception in the market. Following the split, the outstanding ordinary shares will decrease from approximately 50.3 million to about 2.5 million. EUDA, with its basis in Singapore and focus on non-invasive healthcare, aims to lead the preventive care sector amid shifting demographics in Asia.
Read more →-EUDA
Mar 4, 2026EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant SINGAPORE
EUDA Health Holdings Limited has announced the successful repurchase and cancellation of a warrant issued to Streeterville Capital, LLC, eliminating the potential issuance of 2,000,000 ordinary shares. The repurchase was completed for a total of US$125,000 as part of a securities purchase agreement made in November 2025. This strategic action demonstrates EUDA's commitment to maintaining shareholder value while focusing on the growing longevity healthcare market in Asia.
Read more →-EUDA
Jan 15, 2026EUDA Health Announces Second Amendment to Streeterville Warrant Agreement SINGAPORE
EUDA Health Holdings Limited has announced a second amendment to its warrant agreement with Streeterville Capital, reducing the exercise price from $4.00 to $2.00 per share. This adjustment also lowers the minimum closing price requirement for forced exercise from $6.00 to $3.00. CEO Alfred Lim stated that this change is aimed at aligning the warrant terms with current market conditions while maintaining focus on the company's long-term strategy. The company continues to prioritize preventive and longevity-focused healthcare solutions in Asia.
Read more →-EUDA
Jan 13, 2026EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform SINGAPORE
EUDA Health Holdings Limited has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd., marking a strategic expansion of its stem cell therapy platform. The agreement involves an investment of up to RMB 6 million, aimed at enhancing Shenzhen Inno's production and innovation capabilities. This investment will serve as a core hub for EUDA's operations in China and is structured to enable potential equity conversion in the future. With strong institutional backing and a focus on advanced cellular therapeutics, EUDA continues to position itself as a leader in non-invasive healthcare in Asia.
Read more →-EUDA
Jan 7, 2026EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement SINGAPORE
EUDA Health Holdings Limited has announced an amendment to its warrant agreement with Streeterville Capital, reducing the exercise price from $6.00 to $4.00 per share. This amendment may stimulate warrant exercises and further involvement in EUDA's growth strategy. The company operates in the non-invasive healthcare sector in Asia, targeting key markets like Singapore, Malaysia, and China, and focuses on addressing the needs of an aging population. EUDA aims to become a leader in longevity-focused healthcare solutions.
Read more →-EUDA
Dec 30, 2025EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital SINGAPORE
EUDA Health Holdings Limited has announced the launch of a nationwide stem cell extraction, cryostorage, and clinical delivery platform in China. This initiative is in collaboration with Shenzhen Inno Immune and Wuhan Kaien Hospital, aiming to enhance accessibility to regenerative medicine across the region. The platform is designed to ensure centralized quality control while providing decentralized access for patients. This expansion reflects EUDA's commitment to transforming healthcare in Asia with a focus on longevity and preventive care.
Read more →-EUDA
Dec 29, 2025EUDA Health to Launch EUDA Helix 2.0 in January 2026 SINGAPORE
EUDA Health Holdings Limited has announced the upcoming launch of its enhanced supplement, EUDA Helix 2.0, set for January 2026. The new version features an upgraded formulation with increased potency due to a rise in deer placenta powder and a shift from L-glutathione to Vitamin E for better antioxidant stability. Additionally, EUDA Helix 2.0 employs advanced preservation and delivery technologies aimed at enhancing nutrient absorption and extending shelf life. The product has also secured New Zealand Halal certification, enabling broader distribution across international markets, particularly in Muslim regions.
Read more →-EUDA
Dec 23, 2025EUDA Accelerates Longevity Strategy with Launch of Comprehensive Stem Cell Therapy Platform and First Clinic in Shenzhen SINGAPORE
EUDA Health Holdings Limited has announced the launch of a comprehensive stem cell therapy platform and the establishment of its first clinic in Shenzhen, China. This initiative aims to accelerate its longevity and regenerative medicine strategy, supported by strategic partnerships and advanced technology. The upgraded facility will enhance production capabilities for stem cell treatments, and the new clinic will introduce integrated longevity healthcare services. This move positions EUDA to leverage the growing market for longevity-focused healthcare in Asia.
Read more →-EUDA
Dec 22, 2025EUDA Integrates QB Utility Token to Create a Digital Health and Rewards Platform Across Its Healthcare Ecosystem SINGAPORE
EUDA Health Holdings Limited has announced the integration of the QB utility token into its digital health and rewards platform, enhancing customer engagement across its healthcare services. The token, issued by Hong Kong-based QB Limited, allows customers to earn and redeem rewards for services such as Bioenergy Capsule treatments and supplements. The integration aims to create a unified digital ecosystem, leveraging advanced blockchain infrastructure for secure, traceable transactions. EUDA is positioning itself to lead in the non-invasive healthcare market across Asia with this innovative approach.
Read more →-EUDA
Dec 8, 2025EUDA Plans to Integrate QB Utility Token into Its Healthcare Ecosystem SINGAPORE
EUDA Health Holdings Limited announced its plan to integrate a utility cryptocurrency called QB into its healthcare ecosystem. This initiative aims to create a digital health and rewards platform for payments and access to EUDA's services, enhancing customer engagement through a connection between healthcare and decentralized finance. The QB coins, scheduled for launch in January 2026, will also support EUDA's financial strategies as part of a broader mission to address evolving healthcare needs in Asia. CEO Alfred Lim highlighted the potential of this integration to transform health engagement into tangible economic value.
Read more →-EUDA
Dec 5, 2025EUDA Health Holdings Limited Announces Execution of Securities Purchase Agreement SINGAPORE
EUDA Health Holdings Limited announced a securities purchase agreement with Streeterville Capital for a convertible warrant worth $100,000. This warrant allows for the acquisition of up to 2 million shares at $6 each and is part of the company's strategy to boost capital for growth initiatives. CEO Alfred Lim emphasized the financing's role in expanding EUDA's footprint in the non-invasive healthcare market across Asia, targeting a demographic with changing healthcare needs.
Read more →-EUDA
Oct 23, 2025EUDA Subsidiary CK Health Plus Expands into India in Strategic Partnership with SafeRock India SINGAPORE
EUDA Health Holdings Limited's subsidiary, CK Health Plus, has announced its expansion into India through a strategic partnership with SafeRock India. This collaboration aims to leverage SafeRock India's infrastructure and network to introduce cutting-edge Bioenergy Capsule Therapies and EUDA Helix supplements across major cities like Mumbai and Bangalore. The partnership is designed to address the growing demand for preventive healthcare solutions in the Indian market, aligning with the shift towards healthier lifestyles among consumers.
Read more →-EUDA
Oct 20, 2025EUDA Subsidiary CK Health Plus Secures Malaysia Direct Selling License, Strengthening Its Longevity Business Across Asia SINGAPORE
EUDA Health Holdings Limited's subsidiary, CK Health Plus, has obtained a Direct Selling License from the Malaysian government, enabling it to operate direct selling and multi-level marketing activities. This license will facilitate the nationwide rollout of wellness product distribution and Bioenergy Capsule Centers in Malaysia. CK Health Plus intends to create a sustainable business model that integrates healthcare, education, and entrepreneurship, with a focus on preventive health solutions. The company's strategic expansion reflects its commitment to addressing the healthcare needs of a rapidly aging population in the region.
Read more →-EUDA
Oct 1, 2025EUDA HEALTH HOLDINGS LIMITED AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS June 30
EUDA Health Holdings Limited released its unaudited condensed consolidated balance sheets as of June 30. The report primarily outlines various financial components under US GAAP standards, reflecting on the company's assets, liabilities, and equity. Details include categories such as retained earnings and common stock, among others, although specific financial figures are not disclosed in the text provided.
Read more →-EUDA
Sep 10, 2025EUDA Signs Letter of Intent to Potentially Acquire
EUDA Health Holdings Limited has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd, a Singapore-based biotechnology firm. The acquisition aims to leverage GO POSB's proprietary induced pluripotent stem cell (iPSC) platform, which has wide applications in drug discovery and regenerative medicine. As part of the collaboration, they plan to establish a new iPSC laboratory and cultivation facility in Shenzhen, China, enhancing EUDA's capacity in the longevity sector. This strategic step reinforces EUDA's focus on innovative non-invasive healthcare solutions across Asia.
Read more →-EUDA
Sep 4, 2025EUDA Strategically Expands into T-Cell Immunotherapy - Strengthening Its Stem Cell Therapy Portfolio SINGAPORE
EUDA Health Holdings Limited has secured distribution rights for T-cell immunotherapies in Malaysia, developed by Shenzhen Inno Immune Co. Ltd. This strategic move strengthens EUDA's existing stem cell therapy portfolio and reflects its commitment to advance into the regenerative medicine sector. The T-cell immunotherapy package is priced at USD 8,000, which is significantly lower than traditional costs in other regions, making advanced treatment more accessible. The partnership is supported by significant scientific and institutional backing, setting a strong foundation for EUDA's healthcare solutions.
Read more →-EUDA
Aug 28, 2025EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd SINGAPORE
EUDA Health Holdings Limited announced the signing of a Letter of Intent to potentially acquire Chemokine Pte Ltd. This acquisition, which is subject to due diligence and a 120-day exclusivity period, aligns with EUDA's focus on expanding its offerings in non-invasive healthcare. Chemokine specializes in molecular supplements and gene modulating formulations, including a health supplement that EUDA will distribute. While this acquisition may enhance EUDA's position in the market, it also entails certain uncertainties and risks.
Read more →-EUDA
Aug 26, 2025EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement SINGAPORE
EUDA Health Holdings Limited has announced the acquisition of exclusive worldwide distribution rights for a novel immune health supplement developed by Chemokine Pte. Ltd. This next-generation supplement aims to enhance gene expression and is positioned within EUDA's growing wellness product portfolio. Initially marketed in Singapore, Malaysia, and China, the product utilizes advanced epigenetic technology for improved health outcomes. The company anticipates strong sales performance as it targets outputs of around 500,000 bottles in the upcoming year.
Read more →-EUDA
Apr 24, 2025EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to Offer Stem Cell Therapies to Customers in Singapore and Malaysia
EUDA Health Holdings Limited has announced a strategic partnership with Guangdong Cell Biotech, focusing on offering stem cell therapies in Singapore and Malaysia. Through this collaboration, CK Health, a subsidiary of EUDA, will distribute these therapies, enhancing the company’s healthcare offerings in the region. This agreement represents a shift from an originally planned joint venture to a commercial distribution model, allowing for better alignment with market dynamics. EUDA aims to transform the health and wellness landscape by leveraging Guangdong Cell Biotech's capabilities.
Read more →-EUDA
Dec 16, 2024EUDA Holdings and Guangdong Cell Biotech Explore Potential Strategic Partnership to Advance Biotechnology Innovation - Preliminary Discussions Underway to Establish a Joint Venture SINGAPORE
EUDA Health Holdings Limited is engaging in preliminary discussions with Guangdong Cell Biotech to potentially establish a joint venture aimed at advancing biotechnology innovation. This collaboration seeks to leverage the strengths of both companies in digital healthcare and stem cell technologies to enhance market presence and healthcare offerings in Southeast Asia. While initial optimism is expressed regarding this partnership, it remains uncertain as no formal agreement has been reached yet.
Read more →-EUDA
Oct 10, 2024FORTRESS COVE LIMITED INDEX OF FINANCIAL STATEMENTS Financial Statements Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheet as of
Fortress Cove Limited's financial statements for the period ending December 31, 2023, indicate significant operational losses and a working capital deficit. The company, which has been in operation since its inception on November 2, 2023, reported a net loss of $19,788 and highlighted doubts regarding its ability to continue as a going concern due to its financial position. There are also indications that adjustments may be required to reflect the company's uncertain future in its financial reporting. Overall, the current fiscal outlook appears bleak for Fortress Cove Limited as it navigates these challenges.
Read more →-EUDA
May 8, 2024EUDA Health Holdings Limited Completes Acquisition of CK Health Plus Sdn Bhd, Expanding into Direct Selling Holistic Wellness Products in Southeast Asia Singapore
EUDA Health Holdings Limited has successfully completed its acquisition of CK Health Plus Sdn Bhd, marking a significant strategic expansion into the Malaysian market. This move enables EUDA to leverage CK Health's distribution network and product offerings, enhancing its ability to deliver holistic wellness solutions. CEO Dr. Kelvin Chen expressed enthusiasm about the synergies created by the acquisition, which align with EUDA's mission to empower healthier living through innovative technology. The partnership is expected to benefit both companies and the communities they serve by improving health outcomes in Southeast Asia.
Read more →-EUDA
May 6, 2024EUDA Health Expands into Direct Selling Holistic Wellness Products with Acquisition of CK Health SINGAPORE
EUDA Health Holdings Limited has announced its acquisition of CK Health Plus Sdn Bhd, a direct seller of holistic wellness products in Malaysia, for approximately $15 million through newly issued shares. This move is aimed at enhancing EUDA's portfolio of healthcare solutions and leveraging CK Health's unique product offerings, particularly in non-invasive therapies. The acquisition is expected to close on May 8, 2024, contingent on customary conditions. This strategic expansion is positioned to tap into the growing demand for holistic wellness in Southeast Asia's healthcare market.
Read more →-EUDA
Jan 16, 2024EUDA Health Holdings Limited Has Received Nasdaq Notification Regarding Minimum Market Value Deficiency Singapore.
EUDA Health Holdings Limited has received a notification from Nasdaq indicating that it has failed to maintain the required minimum market value of $35 million for its listed securities. The MVLS Notice gives the company until July 8, 2024, to regain compliance. If the company fails to meet this requirement within the designated period, it may face delisting from the Nasdaq stock exchange. This situation poses significant risks for the company's future and its investors.
Read more →-EUDA
May 19, 2023EUDA Health Holdings Limited Announces Receipt of Nasdaq Listing Delinquency Letter Singapore
EUDA Health Holdings Limited has received a delinquency notification letter from Nasdaq due to its failure to timely file its Quarterly Report on Form 10-Q. This follows a similar notice received earlier for not submitting the Annual Report on Form 10-K. The company has until June 5, 2023, to propose a plan for regaining compliance, with a potential extension until September 27, 2023, to file the required reports. Failure to comply may result in the delisting of its securities from Nasdaq.
Read more →-EUDA
Feb 15, 2023EUDA HEALTH HOLDINGS LIMITED Board of Director Officer Letter
EUDA Health Holdings Limited has formally invited Chee Hyong Leonard Chia to join its Board of Directors as a Class II director. The appointment emphasizes the company’s commitment to strong governance practices. Notably, Chia has agreed not to receive compensation for his service, though he will be reimbursed for reasonable travel expenses related to board activities. This move signals an effort to foster board participation while maintaining integrity in governance.
Read more →-EUDA
Nov 23, 2022Euda Health Limited and Subsidiaries Index to Unaudited Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of
Health Limited and Subsidiaries to Unaudited Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of September 30, 2022 (Unaudited) and December 31, 2021 (Audited) 2 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Inc
Read more →-EUDA
Nov 10, 2022i Acquisition 2 Corp. Announces Approval of Business Combination and Ability of Shareholders to Withdraw Ordinary Shares Tendered for Redemption Singapore
Acquisition 2 Corp. Announces Approval of Business Combination and Ability of Shareholders to Withdraw Ordinary Shares Tendered for Redemption November 10, 2022 /PRNewswire/ - 8i Acquisition 2 Corp. (NASDAQ: LAX, the "Company"), a special purpose acquisition company, announced
Read more →-EUDA
Jun 10, 2022i Acquisition 2 Corp. and EUDA Health Limited Announce Amendment to Share Purchase Agreement Singapore
Acquisition 2 Corp. and EUDA Health Limited Announce Amendment to Share Purchase Agreement June 10, 2022 - 8i Acquisition 2 Corp. (the "Company" or "LAX") (NASDAQ: LAX), a publicly traded special purpose acquisition company, and EUDA Health Limited ("EUDA Health"), a Singapore-
Read more →-EUDA
May 31, 2022i Acquisition 2 Corp. and EUDA Health Limited Announce Extension of Due Diligence Review Period Singapore
Acquisition 2 Corp. and EUDA Health Limited Announce Extension of Due Diligence Review Period May 31, 2022 - 8i Acquisition 2 Corp. (the "Company" or "LAX") (NASDAQ: LAX), a publicly traded special purpose acquisition company, and EUDA Health Limited, a Singapore-based digital
Read more →-EUDA
Apr 12, 2022i Acquisition 2 Corp. to Combine with EUDA Health Limited to Bring a Leading Digital Health Platform Servicing Southeast Asia to the Public Market EUDA Health is disrupting the multi-trillion-dollar Southeast Asia health
Acquisition 2 Corp. to Combine with EUDA Health Limited to Bring a Leading Digital Health Platform Servicing Southeast Asia to the Public - April 12, 2022 - EUDA Health Limited, a Singapore-based digital health platform that aims to make healthcare more affordable, accessible,
Read more →-EUDA
Dec 14, 2021i Acquisition 2 Corp. Announces the Separate Trading of its Ordinary Shares, Warrants and Rights, Commencing
Acquisition 2 Corp. Announces the Separate Trading of its Ordinary Shares, Warrants and Rights, Commencing December 14, 2021 December 13, 2021 - 8i Acquisition 2 Corp. (NASDAQ: LAXXU) (the "Company"), a newly organized blank check company incorporated as a British Virgin Island
Read more →-EUDA
Nov 24, 2021I ACQUISITION 2 CORP INDEX TO FINANCIAL STATEMENT Page Report of Independent Registered Public Accounting Firm F-2 Financial Statement: Balance Sheet as of
TO FINANCIAL STATEMENT Page Report of Independent Registered Public Accounting Firm F-2 Financial Statement: Balance Sheet as of November 24, 2021 F-3 Notes to the Financial Statement F-4 OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM the Board of Directors and of 8i Acqu
Read more →-EUDA
Nov 22, 2021i Acquisition 2 Corp. Announces Pricing of $75 Million Initial Public Offering Singapore
Acquisition 2 Corp. Announces Pricing of $75 Million Initial Public Offering November 22, 2021 - 8i Acquisition 2 Corp. (the "Company"), a newly organized blank check company incorporated as a British Virgin Islands business company and led by Chief Executive Officer, Meng Dong
Read more →Competitive Position
How EUDA ranks across every disease it competes inCompetitive Position is a premium feature
See how EUDA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial